EP Patent

EP3297609A1 — Pharmaceutical compositions

Assigned to Novartis AG · Expires 2018-03-28 · 8y expired

What this patent protects

The present invention relates to pharmaceutical compositions comprising the drug substance ( R,E )- N -(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1 H -benzo[d]imidazol-2- yl)-2-methylisonicotinamide, and processes to prepare said pharmaceutical compositions.

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising the drug substance ( R,E )- N -(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1 H -benzo[d]imidazol-2- yl)-2-methylisonicotinamide, and processes to prepare said pharmaceutical compositions.

Drugs covered by this patent

Patent Metadata

Patent number
EP3297609A1
Jurisdiction
EP
Classification
—
Expires
2018-03-28
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.